Buscar
Radiopharm Theranostics Ltd
RADXAñadir a la lista de seguimiento
3.080USD
-0.120-3.75%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
0.00Cap. mercado
--P/E TTM
Más Datos de Radiopharm Theranostics Ltd Compañía
Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.
Información de Radiopharm Theranostics Ltd
Símbolo de cotizaciónRADX
Nombre de la empresaRadiopharm Theranostics Ltd
Fecha de salida a bolsaNov 25, 2021
Director ejecutivoCanevari (Riccardo)
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscal- -
DirecciónLevel 3, 62 Lygon Street
CiudadMELBOURNE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísAustralia
Código postal3053
Teléfono61398245254
Sitio Webhttps://radiopharmtheranostics.com/
Símbolo de cotizaciónRADX
Fecha de salida a bolsaNov 25, 2021
Director ejecutivoCanevari (Riccardo)
Ejecutivos de Radiopharm Theranostics Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Riccardo Canevari
Mr. Riccardo Canevari
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Mr. Paul Hopper
Mr. Paul Hopper
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Thomas H. (Thom) Tulip, Ph.D.
Dr. Thomas H. (Thom) Tulip, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Dimitris Voliotis, M.D.
Dr. Dimitris Voliotis, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Hester Larkin
Ms. Hester Larkin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ian Turner
Mr. Ian Turner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Phillip Hains
Mr. Phillip Hains
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Bruce Goodwin
Mr. Bruce Goodwin
Non-Executive Director
Non-Executive Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Riccardo Canevari
Mr. Riccardo Canevari
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Mr. Paul Hopper
Mr. Paul Hopper
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Thomas H. (Thom) Tulip, Ph.D.
Dr. Thomas H. (Thom) Tulip, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Dimitris Voliotis, M.D.
Dr. Dimitris Voliotis, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Hester Larkin
Ms. Hester Larkin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ian Turner
Mr. Ian Turner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Radiopharm Theranostics Ltd?
Los cinco principales accionistas de Radiopharm Theranostics Ltd son: Mr. Riccardo Canevari
¿Cuántas instituciones poseen acciones de Radiopharm Theranostics Ltd (RADX)?
A fecha de 2026Q1, 11 instituciones poseen acciones de Radiopharm Theranostics Ltd, con un valor de mercado combinado de aproximadamente 51.39M, lo que representa el 3.30% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 50862187.00.